6 analysts have a "Moderate Buy" consensus for Vir Biotechnology, with a $33 avg 12-month target price.
Vir Biotechnology, Inc. (NASDAQ:VIR) has a "Moderate Buy" consensus recommendation from six analysts covering the firm, with an average 12-month target price of $33.00. The company, which focuses on immunology treatments for serious infectious diseases, has seen recent price target revisions from brokerages including Morgan Stanley, Needham & Company LLC, HC Wainwright, JPMorgan Chase & Co., and Barclays. Institutional investors own 65.32% of Vir Biotechnology's stock.
August 17, 2024
5 Articles